7月8日，药明生物盘中下跌3.05%，报35.66港元/股，成交额9.42亿港元。
消息面上，生命科学工具和服务板块连续第二日普遍走弱，药明康德跌3.33%，药明合联跌3.88%，金斯瑞生物科技跌1.33%，晶泰控股跌1.41%，板块共振效应显著。值得注意的是，公司持续维持高频回购节奏，7月7日再度斥资约9982万港元回购271.65万股，自5月26日以来累计回购超3710万股、总代价逾11.72亿港元，但回购力度未能阻止股价随板块回落。此前瑞银上调公司目标价至51.1港元并维持买入评级，当前股价较目标价仍有较大折让。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.